[18F]FCH PET-CT seems to become a useful imaging tool to solve the clinical problem of rising serum prostate-specific antigen (PSA) after initially treated prostate cancer [3]–[5], with PET-CT sensitivity being proportionally related to the PSA level [6], [7]. The gene discussed is KLK3; the disease is prostate carcinoma.